18 October 2018 - The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available to eligible skin cancer patients, after cost regulators published guidance backing funds for the treatment.

NICE has recommended the combination for use in patients with stage III BRAF V600 mutation-positive melanoma who have disease that has spread to lymph vessels, or lymph glands close to the melanoma and who have already had surgery to remove the tumour and associated lymph glands.

To date, this patient group had almost no other treatment options following surgery, aside from radiotherapy in some circumstances, but in over half of cases the cancer recurs, increasing the risk of progressing to the most advanced and incurable stage of the disease.

Read Pharma Times article